Kamada Licenses Alvotech Biosimilars In Israel
First Launch, Teriparatide, Is Slated For 2022
Israel’s Kamada has struck a licensing deal with Alvotech that gives it rights to several of the firm’s biosimilars in its domestic market. The first launch, of the teriparatide biosimilar co-developed with Pfenex, is planned for 2022.
You may also be interested in...
Israel’s Kamada Eyes $40m Sales As Alvotech Alliance Increases
Following on from its initial 2019 alliance, Israel’s Kamada has added a further two biosimilar products to its local distribution agreement with Alvotech. The firm’s CEO discussed its planned foray into the biosimilar space as part of a letter to shareholders.
Kamada Plans Three More Biosimilar Launches In Israel
Israeli firm Kamada has entered into two agreements for commercialization of three biosimilars in Israel. The company expects to launch the products between 2022 and 2024.
Teva Takes Tuznue Trastuzumab Biosimilar In Israel From Prestige
Prestige BioPharma is continuing to put pen to paper on deals to supply and sell its HD201 biosimilar trastuzumab candidate, this time partnering with Israeli giant Teva for local commercialization rights.